Device Trial Radar · NCT07588672
Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Jul 15, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Polyrizon Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- May 15, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the efficacy, safety, and tolerability of PL-14 Allergy Blocker compared to saline spray in adults with Seasonal Allergic Rhinitis (SAR). PL-14 Allergy Blocker is a non-pharmacological, drug-free intranasal mucoadhesive hydrogel designed to form a mechanical barrier on the nasal mucosa and reduce contact between airborne allergens and the nasal lining. This is a prospective, randomized, single-blind, multi-center clinical investigation in up to 120 participants at up to 8 sites in the United States. Eligible participants with a history of seasonal allergic rhinitis will be randomized in a 1:1 ratio to receive either PL-14 Allergy Blocker or Ayr® Saline Nasal Mist for up to 30 days. The study will evaluate the effect of PL-14 Allergy Blocker on nasal allergy symptoms, quality of life, rescue medication use, and symptom-free days. Safety and local tolerability assessments will also be performed throughout this study period.
Conditions
- Seasonal Allergic Rhinitis (SAR)
- Allergic Rhinitis
Interventions
PL-14 Allergy BlockerDevice
PL-14 Allergy Blocker is a non-pharmacological, drug-free intranasal mucoadhesive hydrogel designed to act as a mechanical barrier in the nasal cavity to reduce contact between inhaled allergens and the nasal mucosa.
Ayr® Saline Nasal MistDevice
Ayr® Saline Nasal Mist is a non-medicated isotonic saline nasal spray used as the control comparator in this study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in mean daily reflective Total Nasal Symptom Score (rTNSS) between treatment groupsTime frame: 14 treatment days
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Sneeze, Wheeze & Itch Associates LLC
Normal, Illinois · Recruiting
The Clinical Research Center, LLC
St Louis, Missouri · Recruiting
Allergy Partners of NJ, PC
Ocean City, New Jersey · Recruiting
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.